PMC:7205724 / 21808-23259 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T159","span":{"begin":32,"end":41},"obj":"Body_part"},{"id":"T160","span":{"begin":190,"end":198},"obj":"Body_part"},{"id":"T161","span":{"begin":280,"end":288},"obj":"Body_part"},{"id":"T162","span":{"begin":335,"end":339},"obj":"Body_part"},{"id":"T163","span":{"begin":565,"end":569},"obj":"Body_part"},{"id":"T164","span":{"begin":952,"end":962},"obj":"Body_part"},{"id":"T165","span":{"begin":996,"end":1000},"obj":"Body_part"},{"id":"T166","span":{"begin":1395,"end":1403},"obj":"Body_part"}],"attributes":[{"id":"A159","pred":"fma_id","subj":"T159","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A160","pred":"fma_id","subj":"T160","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A161","pred":"fma_id","subj":"T161","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A162","pred":"fma_id","subj":"T162","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A163","pred":"fma_id","subj":"T163","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A166","pred":"fma_id","subj":"T166","obj":"http://purl.org/sig/ont/fma/fma62851"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T22","span":{"begin":565,"end":569},"obj":"Body_part"},{"id":"T23","span":{"begin":996,"end":1000},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T260","span":{"begin":62,"end":63},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T261","span":{"begin":154,"end":155},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T262","span":{"begin":156,"end":165},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T263","span":{"begin":171,"end":176},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T264","span":{"begin":335,"end":339},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T265","span":{"begin":565,"end":569},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T266","span":{"begin":565,"end":569},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T267","span":{"begin":637,"end":639},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T268","span":{"begin":788,"end":789},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T269","span":{"begin":822,"end":824},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T270","span":{"begin":996,"end":1000},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T271","span":{"begin":996,"end":1000},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T171","span":{"begin":835,"end":846},"obj":"Chemical"},{"id":"T172","span":{"begin":912,"end":918},"obj":"Chemical"},{"id":"T173","span":{"begin":1106,"end":1117},"obj":"Chemical"},{"id":"T174","span":{"begin":1167,"end":1178},"obj":"Chemical"}],"attributes":[{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A172","pred":"chebi_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A173","pred":"chebi_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A174","pred":"chebi_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-MedDRA

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T22","span":{"begin":912,"end":947},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T23","span":{"begin":1395,"end":1410},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A23","pred":"meddra_id","subj":"T23","obj":"http://purl.bioontology.org/ontology/MEDDRA/10035525"},{"id":"A22","pred":"meddra_id","subj":"T22","obj":"http://purl.bioontology.org/ontology/MEDDRA/10033322"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-IDO

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T100","span":{"begin":255,"end":263},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T101","span":{"begin":335,"end":339},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T102","span":{"begin":888,"end":896},"obj":"http://purl.obolibrary.org/obo/OGMS_0000020"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-CHEBI

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T110","span":{"begin":912,"end":918},"obj":"Chemical"}],"attributes":[{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-NCBITaxon

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T216","span":{"begin":171,"end":176},"obj":"Species"},{"id":"T217","span":{"begin":614,"end":622},"obj":"Species"},{"id":"T218","span":{"begin":659,"end":667},"obj":"Species"},{"id":"T219","span":{"begin":1226,"end":1234},"obj":"Species"},{"id":"T220","span":{"begin":1303,"end":1311},"obj":"Species"}],"attributes":[{"id":"A220","pred":"ncbi_taxonomy_id","subj":"T220","obj":"NCBItxid:2697049"},{"id":"A218","pred":"ncbi_taxonomy_id","subj":"T218","obj":"NCBItxid:2697049"},{"id":"A217","pred":"ncbi_taxonomy_id","subj":"T217","obj":"NCBItxid:2697049"},{"id":"A219","pred":"ncbi_taxonomy_id","subj":"T219","obj":"NCBItxid:2697049"},{"id":"A216","pred":"ncbi_taxonomy_id","subj":"T216","obj":"NCBItxid:9606"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-sentences

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T176","span":{"begin":0,"end":41},"obj":"Sentence"},{"id":"T177","span":{"begin":43,"end":61},"obj":"Sentence"},{"id":"T178","span":{"begin":62,"end":112},"obj":"Sentence"},{"id":"T179","span":{"begin":113,"end":441},"obj":"Sentence"},{"id":"T180","span":{"begin":442,"end":523},"obj":"Sentence"},{"id":"T181","span":{"begin":525,"end":542},"obj":"Sentence"},{"id":"T182","span":{"begin":543,"end":622},"obj":"Sentence"},{"id":"T183","span":{"begin":623,"end":770},"obj":"Sentence"},{"id":"T184","span":{"begin":771,"end":989},"obj":"Sentence"},{"id":"T185","span":{"begin":990,"end":1048},"obj":"Sentence"},{"id":"T186","span":{"begin":1049,"end":1128},"obj":"Sentence"},{"id":"T187","span":{"begin":1129,"end":1235},"obj":"Sentence"},{"id":"T188","span":{"begin":1236,"end":1451},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-UBERON

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T22","span":{"begin":565,"end":569},"obj":"Body_part"},{"id":"T23","span":{"begin":996,"end":1000},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-Pubtator

LitCovid-sample-UniProt

LitCovid-sample-Enju

LitCovid-sample-PD-MAT

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T6","span":{"begin":565,"end":569},"obj":"http://purl.obolibrary.org/obo/MAT_0000135"},{"id":"T7","span":{"begin":996,"end":1000},"obj":"http://purl.obolibrary.org/obo/MAT_0000135"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-GO-BP-0

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T31","span":{"begin":100,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T32","span":{"begin":1344,"end":1356},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-FMA

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T159","span":{"begin":32,"end":41},"obj":"Body_part"},{"id":"T160","span":{"begin":190,"end":198},"obj":"Body_part"},{"id":"T161","span":{"begin":280,"end":288},"obj":"Body_part"},{"id":"T162","span":{"begin":335,"end":339},"obj":"Body_part"},{"id":"T163","span":{"begin":565,"end":569},"obj":"Body_part"},{"id":"T164","span":{"begin":952,"end":962},"obj":"Body_part"},{"id":"T165","span":{"begin":996,"end":1000},"obj":"Body_part"},{"id":"T166","span":{"begin":1395,"end":1403},"obj":"Body_part"}],"attributes":[{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A160","pred":"fma_id","subj":"T160","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A163","pred":"fma_id","subj":"T163","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A161","pred":"fma_id","subj":"T161","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A162","pred":"fma_id","subj":"T162","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A159","pred":"fma_id","subj":"T159","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A166","pred":"fma_id","subj":"T166","obj":"http://purl.org/sig/ont/fma/fma62851"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-MONDO

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T159","span":{"begin":100,"end":112},"obj":"Disease"},{"id":"T160","span":{"begin":244,"end":263},"obj":"Disease"},{"id":"T161","span":{"begin":307,"end":327},"obj":"Disease"},{"id":"T162","span":{"begin":329,"end":349},"obj":"Disease"},{"id":"T163","span":{"begin":351,"end":394},"obj":"Disease"},{"id":"T164","span":{"begin":411,"end":440},"obj":"Disease"},{"id":"T165","span":{"begin":570,"end":576},"obj":"Disease"},{"id":"T166","span":{"begin":614,"end":622},"obj":"Disease"},{"id":"T167","span":{"begin":659,"end":667},"obj":"Disease"},{"id":"T168","span":{"begin":1226,"end":1234},"obj":"Disease"},{"id":"T169","span":{"begin":1303,"end":1311},"obj":"Disease"},{"id":"T170","span":{"begin":1344,"end":1356},"obj":"Disease"}],"attributes":[{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A162","pred":"mondo_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/MONDO_0008538"},{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0011429"},{"id":"A160","pred":"mondo_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A163","pred":"mondo_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/MONDO_0018456"},{"id":"A161","pred":"mondo_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A159","pred":"mondo_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-PD-HP

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T9","span":{"begin":244,"end":263},"obj":"Phenotype"},{"id":"T10","span":{"begin":307,"end":327},"obj":"Phenotype"},{"id":"T11","span":{"begin":340,"end":349},"obj":"Phenotype"},{"id":"T12","span":{"begin":365,"end":394},"obj":"Phenotype"},{"id":"T13","span":{"begin":411,"end":440},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0005681"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0012089"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0005681"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sample-GO-BP

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T27","span":{"begin":100,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T28","span":{"begin":1344,"end":1356},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T27","span":{"begin":100,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T28","span":{"begin":1344,"end":1356},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T176","span":{"begin":0,"end":41},"obj":"Sentence"},{"id":"T177","span":{"begin":43,"end":61},"obj":"Sentence"},{"id":"T178","span":{"begin":62,"end":112},"obj":"Sentence"},{"id":"T179","span":{"begin":113,"end":441},"obj":"Sentence"},{"id":"T180","span":{"begin":442,"end":523},"obj":"Sentence"},{"id":"T181","span":{"begin":525,"end":542},"obj":"Sentence"},{"id":"T182","span":{"begin":543,"end":622},"obj":"Sentence"},{"id":"T183","span":{"begin":623,"end":770},"obj":"Sentence"},{"id":"T184","span":{"begin":771,"end":989},"obj":"Sentence"},{"id":"T185","span":{"begin":990,"end":1048},"obj":"Sentence"},{"id":"T186","span":{"begin":1049,"end":1128},"obj":"Sentence"},{"id":"T187","span":{"begin":1129,"end":1235},"obj":"Sentence"},{"id":"T188","span":{"begin":1236,"end":1451},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":244,"end":263},"obj":"Phenotype"},{"id":"T10","span":{"begin":280,"end":305},"obj":"Phenotype"},{"id":"T11","span":{"begin":307,"end":327},"obj":"Phenotype"},{"id":"T12","span":{"begin":340,"end":349},"obj":"Phenotype"},{"id":"T13","span":{"begin":365,"end":394},"obj":"Phenotype"},{"id":"T14","span":{"begin":411,"end":440},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0012089"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0005681"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0005681"}],"text":"6.2 Targeting pro-inflammatory cytokines\n\n6.2.1 Hypothesis: A mAb against IL6 can attenuate hyper inflammation\nTocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis. It is safe and effective for both adults and children two years of age and older.\n\n6.2.2 Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19\nIn the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment.\nThere are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]."}

PMC:7205724 / 21808-23259 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7205724 / 21808-23259 JSON TXT